Biotech hit rock bottom last spring as DOGE ran rampant and President Donald Trump beat the drum for historic tariffs. So for our second-half survey of biotech execs, largely CEOs, we dove right into the …
GSK wins FDA approval for long-acting asthma drug
GSK secured FDA approval for an inflammatory disease drug that it says could reach £3 billion ($4 billion) in peak sales. The agency greenlit depemokimab


